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Introduction
============

Recent developments in spinal surgery implants promise less invasive procedures with superior effectiveness to conventional surgery.[@ref1] Particularly in (older) patients with spinal stenosis due to arthrosis of the facet joints, implantation of an interspinous process device is regularly offered. However, the growing incidence of low back surgery with additional implants for degenerative spine disease has raised questions from the scientific community.[@ref2] [@ref3] Furthermore, the economic burden of management of lumbar spine disorders (lumbar spinal disorder and lumbar disc disease combined) was already worrisome in the 1990s, when they ranked fifth on the basis of cost of hospital care.[@ref4] The increasing use of implants, combined with a growing older population, leads to societal concerns as the cost of the management of spinal stenosis is escalating.[@ref5] [@ref6]

Lumbar degenerative spinal stenosis is caused by arthrosis of the facet joints and development stenosis, which can result in lumbar nerve root compression.[@ref7] As in other acquired diseases, intermittent neurogenic claudication is usually seen in older people.[@ref8] Severe stenosis is common in older people's spines: 30.4% of the Japanese population had a severe stenosis (average age 67.3 (range 40-93) years).[@ref9] Why only 17.5% of these patients have typical symptoms is not yet known. Most of these patients complain of a complex of symptoms, described as leg pain (frequently in both legs), which is exacerbated by walking, prolonged standing, or lumbar extension.[@ref7] [@ref8] [@ref10] [@ref11] Classically, the cramp, tightness, pain, or discomfort in the legs will diminish after a short period of sitting or bending forward.[@ref8] Apart from the leg pain, associated low back pain may occur.[@ref12] The optimum treatment of lumbar spinal stenosis is generally considered to be surgical intervention, as two randomized clinical trials comparing conservative treatment with conventional bony decompression resulted in treatment effects in favor of surgery.[@ref13] [@ref14] The treatment outcome falls short of surgeons' expectations, as surgical decompression yields a modest outcome, being favorable in only 65% of patients.[@ref13] [@ref14] [@ref15] [@ref16] [@ref17] This slightly disappointing success rate is said to be due to the destructive nature of bony decompressive surgery of the spinal column.[@ref18] [@ref19] Instability of the lumbar spine follows laminectomy, requiring subsequent instrumental spondylodesis.[@ref20] [@ref21] Spinal surgeons and the medical device industry are therefore looking for a less detrimental alternative in the surgical care for the older population.

Minimally invasive surgery has gained popularity in recent years, resulting in the development of various interspinous process devices.[@ref22] The interspinous process device was developed to stabilize and increase the interspinous distance with indirect decompression of the dural sac and nerve roots.[@ref23] [@ref24] [@ref25] [@ref26] [@ref27] [@ref28] [@ref29] [@ref30] [@ref31] [@ref32] [@ref33] Treatment of neurogenic claudication with has been shown to be superior to conservative care.[@ref34] [@ref35] [@ref36] The Coflex implant (Paradigm Spine, USA) was developed as a second generation interspinous process device to give indirect decompression with the possibility of stabilizing the lumbar spine after bony decompression. Although some medical societies in Western countries believe in additional pedicle screw fixation of the lumbar spine, the scientific gold standard of surgical treatment of lumbar spinal stenosis is bony decompression.[@ref37] [@ref38] All new surgical techniques to treat lumbar spinal stenosis should be compared with this technique.[@ref13] [@ref14] [@ref16] [@ref39] Although society might be subjected to media driven medicine and early adoption of surgical implants, the spinal scientific community believes that well designed comparative studies should be conducted before a new implant can replace the gold standard. Interspinous process devices have been suggested to have better short term (eight weeks) recovery than and similar long term (cost) effectiveness to bony decompression.[@ref23] [@ref24] [@ref25] [@ref26] [@ref29] [@ref30] [@ref31] [@ref33] [@ref35] [@ref36] [@ref40] [@ref41] The purpose of this study was to assess whether interspinous process device implantation is more effective in the short term than conventional surgical decompression for patients with intermittent neurogenic claudication due to lumbar spinal stenosis.

Methods
=======

We did a prospective, randomized, double blind, multicenter trial among patients with intermittent neurogenic claudication due to lumbar spinal stenosis after failed conservative treatment (Foraminal Enlargement Lumbar Interspinosus distraXion: FELIX trial). We compared minimally invasive treatment with interspinous process devices against usual care (conventional bony decompression). The design and study protocol have been published previously.[@ref42]

Eligibility and randomization
-----------------------------

Patients aged between 40 and 85 years with at least three months of intermittent neurogenic claudication due to single or two level degenerative lumbar canal stenosis and an indication for surgery were eligible. All patients were diagnosed as having intermittent neurogenic claudication by a neurologist in one of the participating hospitals. If magnetic resonance imaging showed a lumbar spinal canal stenosis, the consulting neurosurgeon could include patients as surgical candidates for the study. At the time of enrollment, an independent research nurse verified the persistence of the symptoms. We excluded patients with a cauda equina syndrome, a herniated disc needing discectomy, history of lumbar surgery, or significant scoliosis (Cobb angle \>25°) or other spinal deformities.

We used a randomized design with variable block sizes, with allocations stratified according to center. Allocations were stored in prepared opaque, coded, and sealed envelopes. The key was accessible only to the ProMISe data management system of the Department of Medical Statistics and BioInformatics of the Leiden University Medical Center. All patients gave informed consent. After induction of anesthesia, the prepared envelope was opened and the patient allocated to one of the treatment arms. Patients, nurses on the hospital wards, and research nurses remained blind to the allocated treatment during the follow-up period of one year. The surgical report was kept separately from the patient's regular clinical forms and was available to the neurosurgeon only in case of complications or reoperations.

Interventions
-------------

Patients allocated to the experimental group were operated on under general anesthesia in the knee-elbow position; no bony decompression was done, and an interspinous process device was implanted by a posterior midline approach using radiographic data for localization of the appropriate level. Patients in the standard bony decompression group had surgery in the same knee-elbow position done using a similar incision length to the interspinous process device group to keep all caregivers blind to the allocated treatment. A partial resection of the adjacent laminas was executed, followed by a flavectomy with bilateral opening of the lateral recess. If judged necessary, a medial facetectomy was done. Patients in both groups received the same standard postoperative care. Patients and the research nurses who were following them were asked after every visit if they were still blind to the allocated treatment.[@ref42]

Outcomes
--------

The primary outcome measure was a disorder specific functional score, obtained by the Zurich Claudication Questionnaire.[@ref43] [@ref44] [@ref45] The primary outcome score was assessed at baseline and at 2, 4, 8, 12, 26, and 52 weeks after surgery. The questionnaire consists of three domains (symptom severity, physical function, and patients' satisfaction), in which respectively seven, five, and six questions are answered on a five point (symptom severity) or a four point (physical function and patients' satisfaction) scale. The subscale scores were the averages of the points obtained for every question of the subscale, with a maximum score of 5 for symptom severity and 4 for physical function and patients' satisfaction. The score increases with increasing disability. Blinded research nurses obtained the average subscale scores at every follow-up visit.[@ref42] We considered the overall Zurich Claudication Questionnaire score to represent a "successful recovery" when at least two domain subscales were judged as "success."[@ref46] We defined "success" on the symptom severity scale and on the physical function scale as a decrease of at least 0.5 points; a score of less than 2.5 on the patients' satisfaction subscale represented "success."[@ref44] [@ref45]

Secondary outcome measures were the modified Roland Disability Questionnaire for sciatica (scores range from 0 to 23, with higher scores indicating worse functional status),[@ref47] [@ref48] [@ref49] [@ref50] [@ref51] [@ref52] [@ref53] [@ref54] [@ref55] a 100 mm visual analogue scale for back and leg pain (with 0 representing no pain and 100 the worst pain ever experienced),[@ref56] the Medical Outcomes Study 36 item Short Form Generated Health Survey (SF-36) scale (based on eight scaled scores, which are the weighted sums in their sections),[@ref57] [@ref58] the McGill Pain Questionnaire (with 0 representing minimum pain score and 78 maximum pain score),[@ref59] [@ref60] and a seven point Likert-type self rating scale of global perceived recovery as assessed by the question of whether the patient had experienced recovery (dichotomized into 1-2 for recovery and 3-7 for no recovery).[@ref61] Furthermore, patients underwent a shuttle walking test with a predefined maximum distance and timeframe (1200 m or 15 min).[@ref62] Patients were scored as "success" when they walked 1200 m within 15 minutes or showed an increase of more than 80 m compared with their baseline walking distance.[@ref42] [@ref61] [@ref63] [@ref64] Finally, we used a Hospital Anxiety and Depression Scale consisting of a seven item depression scale and a seven item anxiety scale (4 point scale from 0 to 3).[@ref65] The seven items of the depression scale are related (if more than 8 points) to depression, and the seven items of the anxiety scale are related (if more than 8 points) to generalized anxiety disorder.[@ref66] Most studies report a cut-off point at 8 points. We assessed secondary outcome scores at baseline and at two (only visual analogue scale back and leg pain), eight 12, 26, and 52 weeks. The Hospital Anxiety and Depression Scale anxiety and depression scores were obtained at baseline and after 52 weeks.

Sample size
-----------

The aim of this study was to assess whether the experimental surgical technique with an interspinous process device would be superior to conventional surgery for patients with intermittent neurogenic claudication due to lumbar spinal stenosis on short term outcome scales. Based on our main outcome score (Zurich Claudication Questionnaire) and an assumed minimal clinically important change of 20% difference in the overall success rate between the two groups at eight weeks and 10% loss to follow-up, we calculated that a sample size of 80 patients in each treatment group would be required to provide a statistical power of 0.80 and a two sided α of 0.05.[@ref43] [@ref44] [@ref45] [@ref46] We determined this 20% success rate on the basis of the assumption that superiority would be convincing enough to change the surgical guidelines. Researchers had access to the data only after the full follow-up period of one year.

Statistical analysis
--------------------

We compared groups on the basis of an intention to treat analysis. We analyzed differences between groups at all the follow-up (2, 4, 8, 12, 26, and 52 weeks) time points with repeated measurement analysis. To account for the correlation between repeated measurements of the same person, we used generalized estimating equations. We present the difference between the results for the two groups as an odds ratio for binary outcome variables and as mean differences for continuous outcome variables.[@ref42] To investigate potential bias due to loss to follow-up, we did a sensitivity analysis for the primary outcome by assigning a poor outcome to all missing cases.

At randomization, the administrative center stratified the study for the purpose of analyzing possible heterogeneity among centers and attempting a clinical interpretation of such heterogeneity. We tested heterogeneity between centers by using center as a covariate in the mixed model. We combined those centers that were referring patients to the same hospital and the same surgeon for treatment. Hence, for the analysis of heterogeneity, a center means the actual location where the treatment (according to random allocation) took place. We used the ProMISe data management system of the Department of Medical Statistics and BioInformatics of the Leiden University Medical Center Data for collection of data and checking for quality. We used IBM SPSS software, version 20.0, for all statistical analysis.

Results
=======

Between October 2008 and September 2011, 203 patients with intermittent neurogenic claudication due to spinal stenosis were referred to the Leiden-The Hague Spine Prognostic Study Group. For all patients, the including neurosurgeon confirmed a single or two level, magnetic resonance imaging confirmed, degenerative stenosis and intermittent neurogenic claudication according to the referring neurologists. One hundred and sixty two patients gave informed consent and were enrolled in the FELIX trial (fig 1[](#fig1){ref-type="fig"}). One patient died while waiting for the operation. Two patients were found to have a severe spondylolysis of the L5-S1 segment at the final preoperative check-up and were excluded from the study, because this could cause a detrimental effect in the implant group. The remaining patients were randomly assigned to interspinous process device or decompression, and 159 patients received the allocated treatment. All patients had had intermittent neurogenic claudication for an average period of 23 (intermittent neurogenic claudication group) and 22 (decompression group) months. No significant differences were noted in baseline characteristics between patients in the two treatment arms (table 1[](#tbl1){ref-type="table"}). Seven patients were lost to follow-up in the interspinous process device group and one patient in the bony decompression group.

![**Fig 1** Flow chart of enrollment and follow-up. IPD=interspinous process device](moow013153.f1_default){#fig1}
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Characteristics of patients at baseline. Values are numbers (percentages) unless stated otherwise

  Characteristic                                                             IPD group (n=80)       Decompression group (n=79)
  -------------------------------------------------------------------------- ---------------------- ----------------------------
  Median (range) age (years)                                                 66 (45-83)             64 (47-83)
  Male sex                                                                   49 (61)                37 (47)
  Median (range) duration of intermittent neurogenic claudication (months)   12 (2-120)             22 (1-204)
  Median (range) body mass index\*                                           27 (20-48)             28 (20-37)
  Duration of back pain (categorized)                                        1-3 years              1-3 years
  IPD patient's preferred treatment†                                         39 (49)                36 (46)
  Bony decompression patient's preferred treatment†                          0 (0)                  3 (4)
  No preference for specific treatment†                                      41 (51)                40 (50)
  Mild paresis or sensory loss                                               54 (67)                56 (71)
  Localization of stenosis:                                                                         
  L2-L3                                                                      2 (3)                  3 (4)
  L3-L4                                                                      25 (31)                22 (28)
  L4-L5                                                                      53 (66)                54 (68)
  Operated at two levels:                                                    21 (26)                16 (20)
  L2-L3-L4                                                                   2 (3)                  3 (4)
  L2-L3 and L4-L5                                                            1 (1)                  0 (0)
  L3-L4-L5                                                                   17 (21)                13 (16)
  Zurich Claudication Questionnaire‡:                                                               
  Mean (SD) subscale symptom severity 0-5 scale‡                             3.1 (0.5)              3.2 (0.5)
  Mean (SD) subscale physical function 0-4 scale‡                            2.6 (0.5)              2.6 (0.5)
  Mean (SD) Roland Disability Questionnaire 23 points                        13.0 (5.2)             14.4 (4.5)
  Mean (SD) VAS leg pain (mm)§                                               52 (24)                58 (24)
  Mean (SD) VAS back pain (mm)§                                              60 (44)                49 (25)
  Median (range) SWT (m)¶                                                    180 (20-1260) (n=70)   140 (10-1220) (n=70)
  Completed SWT¶                                                             8 (10)                 13 (16)

IPD=interspinous process device; SWT=shuttle walking distance; VAS=visual analogue scale.

\*Weight in kilograms divided by square of height in meters.

†Patients were asked if they had any treatment preference (no preference, IPD, or bony decompression).

‡Disease specific outcome score; at baseline, score was reported in two subdomains---symptom severity (range 0-5) and physical function (range 0-4).

§Intensity of pain was measured by horizontal 100 mm VAS, with 0 representing no pain and 100 worst pain ever.

¶Obtained before operation; patients were asked to walk until they got symptoms; test was scored "complete" when patients walked 1200 m in 15 min without stopping.

Successful recovery according to the Zurich Claudication Questionnaire at short term follow-up (eight weeks) was achieved by 63% of the patients in the interspinous process device group compared with 72% in the bony decompression group (odds ratio 0.73; P=0.44. Long term (one year) successful recovery according to the Zurich Claudication Questionnaire was similar in the two groups, resulting in 66% good results in the interspinous process device group and 69% in the bony decompression group (odds ratio 0.90; P= 0.77). Overall, the Zurich Claudication Questionnaire analysis showed no differences between the two treatment arms (table 2[](#tbl2){ref-type="table"}; fig 2[](#fig2){ref-type="fig"}).

![**Fig 2** Scores on Zurich Claudication Questionnaire (top), modified Roland Disability Questionnaire (middle), and visual analogue scale (bottom) in two groups during follow-up. IPD=interspinous process device](moow013153.f2_default){#fig2}
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Primary and secondary outcomes\*

  Variable                                    Baseline (n=159)                            2 weeks (n=129)                        8 weeks (n=142)                         26 weeks (n=141)                      52 weeks (n=144)                                                                                                                     
  ------------------------------------------- --------------------- --------------------- ----------------- -------------------- -------------------- ------------------ ------------------ ------------------ ------------------ ------------------ -- --------------- --------------- ------------------ -- ------------------ ------------------ ------------------
  **Primary outcome**                                                                                                                                 **OR (P value)**                                                            **OR (P value)**                                      **OR (P value)**                                            **OR (P value)**
  \% (95% CI) success ZCQ                     NA                    NA                                      67 (55 to 77)        57 (45 to 69)        1.64 (0.18)                           63 (51 to 73)      72 (60 to 81)      0.73 (0.44)           64 (53 to 74)   63 (50 to 74)   1.20 (0.64)           66 (54 to 74)      69 (57 to 78)      0.90 (0.77)
  **Secondary outcomes**                                                                                                                              **MD**                                                                      **MD**                                                **MD**                                                      **MD**
  Mean (95% CI) MRDQ (23 points) score        13.0 (11.7 to 14.2)   14.4 (13.3 to 15.5)                     10.4 (9.2 to 11.8)   10.6 (9.3 to 12.0)   0.1                                   7.5 (6.1 to 9.0)   6.5 (5.3 to 7.8)   1.0                   NA              NA              NA                    6.9 (5.4 to 8.5)   8.1 (6.6 to 9.7)   1.2 (0.28)†
  Mean (95% CI) VAS back pain (0-100 mm)      60 (37 to 83)         49 (44 to56)                            32 (27 to38)         33 (28 to39)         1                                     24 (19 to 30)      23 (17 to 28)      1                     NA              NA              NA                    23 (17 to 29)      31 (24 to 37)      8 (0.09)†
  Mean (95% CI) VAS leg pain (0-100 mm)       52 (47 to 59)         58 (52 to 64)                           23 (18 to 28)        26 (20 to 32)        3                                     26 (20 to 32)      22 (18 to 27)      4                     NA              NA              NA                    23 (17 to 30)      26 (20 to 33)      3 (0.54)†
                                                                                                                                                                                                                                  **OR (P value)**                                                                                                  **OR (P value)**
  Mean (95% CI) Likert % perceived success‡   NA                    NA                                      NA                   NA                   NA                                    51 (40 to 63)      53 (41 to 64)      0.94 (0.85)           NA              NA              NA                    56 (45 to 67)      49 (38 to 60)      1.37 (0.37)

BD=bony decompression; IPD=interspinous process device; MD=mean difference; MRDQ=modified Roland Disability Questionnaire; NA=test not administered; OR=odds ratio; VAS=visual analogue scale; ZCQ=Zurich Claudication Questionnaire.

\*Outcomes were analyzed with generalized estimating equations (GEE). Outcome was reported as odds ratio for better success rate when treated with IPD versus bony decompression and overall P value (based on GEE) of interaction between two groups based on continuous outcome scales with mean differences (MRDQ and VAS).

†Overall score in continuous outcome scales were not significant (MRDQ and VAS).

‡Likert global perceived recovery defined by 7 point scale from "worse" to "complete" recovery; score was dichotomized between good recovery (1-2) and bad recovery (3-7).

Modified Roland Disability Questionnaire values at eight weeks recovered by a mean score of 7.5 for patients treated with interspinous process device and by a mean score of 6.5 for those treated with bony decompression (P=0.28). Generalized estimating equations analysis showed no differences between the two treatment arms (table 2[](#tbl2){ref-type="table"}; fig 2[](#tbl2){ref-type="table"}). Analysis of all other subscales---visual analogue scale back pain (P=0.09), visual analogue scale leg pain (P=0.54), McGill Pain Questionnaire (P=0.70), and Likert scale for perceived recovery (P=0.37)---showed no differences during the complete follow-up (table 2[](#tbl2){ref-type="table"}; fig 2[](#fig2){ref-type="fig"}). We found no statistically significant difference in walking distance in the shuttle walking test at eight weeks (odds ratio 0.75; P=0.33) and 52 weeks (1.25; P=0.54) between the two treatment groups. Generalized estimating equations analysis on visual analogue scale back pain and leg pain, SF-36, McGill Pain Questionnaire, Likert score for perceived recovery, shuttle walking test, and Hospital Anxiety and Depression Scale scores also showed no differences (tables 2[](#tbl2){ref-type="table"} and 3[](#tbl3){ref-type="table"}). We did not adjust primary outcome scores for Hospital Anxiety and Depression Scale depression because of the small percentage of participants with a score of 8 or more (indicating depression).

###### 

Secondary outcomes at 8 and 52 weeks\*

  Outcome                                                  IPD                        Decompression              Odds ratio† (P value)
  -------------------------------------------------------- -------------------------- -------------------------- -----------------------
  \% success (95% CI) on shuttle walking test:                                                                   
  8 weeks (increase of 80 m or complete)                   57 (0.45 to 0.68) (n=73)   59 (0.47 to 0.88) (n=72)   0.75 (0.33)
  52 weeks (increase of 80 m or complete)                  57 (0.43 to 0.69) (n=66)   51 (0.40 to 0.62) (n=70)   1.25 (0.54)
  Mean (95% CI) SF-36 score:                                                                                     
  Bodily pain 8 weeks                                      66 (61 to 71)              63 (58 to 68)              (0.40)‡
  Bodily pain 52 weeks                                     66 (60 to 72)              62 (57 to 68)              
  Physical functioning 8 weeks                             64 (59 to 70)              67 (62 to 72)              (0.72)‡
  Physical functioning 52 weeks                            63 (58 to 69)              62 (56 to 68)              
  Social functioning 8 weeks                               74 (69 to 80)              76 (70 to 82)              (0.95)‡
  Social functioning 52 weeks                              77 (70 to 83)              77 (72 to 82)              
  Physical role 8 weeks                                    44 (34 to 54)              42 (33 to 51)              (0.96)‡
  Physical role 52 weeks                                   55 (45 to 65)              55 (46 to 65)              
  Emotional role 8 weeks                                   74 (65 to 83)              80 (72 to 88)              (0.46)‡
  Emotional role 52 weeks                                  74 (65 to 83)              79 (71 to 87)              
  Mental health index 8 weeks                              77 (73 to 81)              76 (72 to 80)              (0.92)‡
  Mental health index 52 weeks                             75 (70 to 80)              75 (71 to 79)              
  Vitality 8 weeks                                         64 (60 to 68)              62 (58 to 67)              (0.60)‡
  Vitality 52 weeks                                        61 (56 to 66)              59 (55 to 64)              
  General health perception 8 weeks                        67 (63 to 71)              63 (59 to 67)              (0.34)‡
  General health perception 52 weeks                       62 (57 to 67)              59 (55 to 63)              
  Mean (95% CI) McGill Pain Questionnaire (0-78 points):                                                         
  8 weeks                                                  11 (9 to 12)               10 (8 to 12)               
  52 weeks                                                 11 (9 to 13)               10 (9 to 12)               (0.70)‡
  Median (range) HADS depression score§:                                                                         
  Baseline                                                 4 (0-9)                    3 (1-9)                    
  52 weeks                                                 3 (0-9)                    3 (0-9)                    
  Median (range) HADS anxiety score§:                                                                            
  Baseline                                                 7 (2-14)                   6 (2-12)                   
  52 weeks                                                 6 (1-12)                   6 (0-14)                   
  No (%) reoperations                                      21 (29)                    6 (8%)                     (\<0.001)§
  No (%) ZCQ success of reoperated patients                10 (48)                    3 (50)                     
  No (%) operated at two levels                            21 (26)                    16 (18)                    
  No of reoperations in patients operated at two levels    8                          1                          (0.03)§
  \% (95% CI) ZCQ success at 8 weeks                       67 (45 to 83)              48 (24 to 73)              2.50 (0.06)
  \% (95% CI) ZCQ success at 52 weeks                      49 (29 to 69)              53 (25 to 79)              0.83 (0.83)
  Mean (95% CI) duration of operation (min)                24 (22 to 26)              43 (39 to 47)              (\<0.001)\*\*
  Blood loss (mL)---categorized¶                           10-50                      50-100                     (\<0.001)\*\*
  Complications during hospital stay                       5                          6                          
  Spinous process fractures                                3                          ††                         ††
  Mean (SD) hospital stay                                  1.83 (0.9)                 1.89 (1.2)                 (0.753)\*\*
  No (%) blinded to allocated treatment                    54 (67)                    68 (86)                    

HADS=Hospital Anxiety and Depression Scale; IPD=interspinous process device; ZCQ=Zurich Claudication Questionnaire.

\*Outcomes were analyzed with generalized estimating equations (GEE).

†Odds ratio for better success rate when treated with IPD versus bony decompression, based on GEE.

‡Overall P value (based on GEE) of interaction between two groups based on continuous outcome scale (SF-36 and McGill).

§Score consists of sum score of 7 item (0-3 points per item) questionnaire ranging from 0 to 21 points; HADS-anxiety \>8 is suspect for generalized anxiety disorder; HADS-depression \>8 is suspect for depression.

¶0-10 mL, 10-50 mL, 50-100 mL, 100-200 mL.

\*\*P value with Fisher's exact test and Pearson χ^2^.

††Spinous process fractures were not registered as relevant complications in bony decompression group, so no comparison (or P value).

Surgery time (24 min) was shorter in the interspinous process device group than for bony decompression (43 min) (P\<0.001). Blood loss was less in the interspinous process device group (10-50 mL) than in the bony decompression group (50-100 mL) (P\<0.001). Five direct (that is, during the initial hospital stay) postoperative complications occurred in the interspinous process device: one patient with short term (48 hours) unexplained visual disturbance, one patient with self limiting pseudoradicular pain in the other leg, and three patients with interspinous process fractures during interspinous process device placement (table 3[](#tbl3){ref-type="table"}). Direct postoperative complications occurred in six patients in the bony decompression group: two patients with direct epidural hematoma needing reoperation and four patients with dural tears without further consequences. Late reoperation due to absence of recovery was indicated and performed in 21/73 (29%) cases in the interspinous process device group compared with 6/72 (8%) in the bony decompression group (P\<0.001). Of patients who initially received an interspinous process device and were reoperated (explantation of the device and subsequent bony decompression), 48% scored successful recovery on the Zurich Claudication Questionnaire; of patients in the bony decompression group who were reoperated, 50% scored successful recovery. The Zurich Claudication Questionnaire outcome of the patients reoperated after interspinous process device placement did not differ significantly from that of the other patients (P=0.08). Average hospital stay was similar in both groups: 1.83 days for the interspinous process device group and 1.89 days for the bony decompression group (P=0.753). Patients were successfully blinded to the treatment chosen in 67% of the IPD group and 86% of the standard decompression group.

We did a sensitivity analysis to assess the effect of the missing values for our primary outcome. Firstly, we replaced all missing values with unfavorable outcomes. This did not affect our results in any substantial way. Next, we replaced all missing values with favorable outcomes. Again, we saw no substantial changes to our results. The results for the primary outcome were therefore not sensitive to loss to follow-up.

Thirty seven patients were operated on at two levels (tables 1[](#tbl1){ref-type="table"} and 3[](#tbl3){ref-type="table"}). The subgroup of patients with lumbar spinal stenosis operated on at two levels with an interspinous process device (21 patients) had a similar outcome on the Zurich Claudication Questionnaire scale at eight weeks (odds ratio 2.5; P=0.06) and at one year (0.83; P=0.83) to those allocated to the bony decompression group (18 patients). Generalized estimating equations analysis showed no difference in Zurich Claudication Questionnaire results between one and two levels of surgery (P=0.44). However, the reoperation rate of 38% (eight patients) in the interspinous process device group at two levels was higher than the reoperation rate in the bony decompression group of 6% (one patient) (P\<0.05).

We found no clinically significant heterogeneity in the outcomes between the five centers (supplementary appendix). The small difference supports the contention that the sample of hospitals is a good representation of the Dutch healthcare system.

Discussion
==========

Implantation of an interspinous process device as definite treatment for lumbar spinal stenosis did not show the hypothesized short term superior effect over standard bony decompressive surgery. The one year follow-up results of both surgical procedures did not differ, although the reoperation rate for the interspinous process device was significantly higher than that for conventional bony decompression. Another study started in 2007 was terminated when an interim analysis showed a fourfold higher reoperation rate in the interspinous process device group.[@ref67] The shorter operation time was the only beneficial parameter for patients in the interspinous process device group compared with the bony decompression group, but this did not result in a shorter hospital stay. Furthermore, patients operated on at two levels had an even higher reoperation rate compared with bony decompression. The absence of short term added value of the interspinous process device and the much higher reoperation rate in this study do not allow this new procedure to replace the golden standard of simple bony decompression as treatment for lumbar spinal stenosis.

Strengths and limitations of study
----------------------------------

One of the strengths of this study is that this is the first and only blinded randomized study on this subject. Furthermore, by anomyzation during data analysis, we excluded bias as much as possible. However, the study has also features that may limit the generalizability of its findings. Firstly, selection bias could have been introduced through the opinion of the including neurosurgeon that patients with severe spinal stenosis on magnetic resonance imaging should not be offered an interspinous process device and were thus not included in the FELIX trial. However, clinical features of the patients included in this study showed baseline values (mean visual analogue scale (leg and/or back) of 60 mm at baseline) comparable to those of other large trials.[@ref13] [@ref14] Trials in general tend to include standard patients, but, as mentioned earlier, not all patients with stenosis have clinical complaints, which could lead to potential bias that may limit the generalizability. The number of reoperations in the interspinous process device treatment arm is very worrisome, especially because reoperations do not reach the success rate of primary surgeries; use of interspinous process devices might even prevent recovery in 20% of patients. Lastly, shuttle walking tests are believed to be the most objective parameter to classify the disease specific complaints of lumbar spinal stenosis. As in many other studies, however, using this test for an older population is often difficult.[@ref13] Further research should focus on finding a new objective parameter to evaluate the increasingly older population with lumbar spinal stenosis.

Comparison with other studies
-----------------------------

Others researchers have tested the interspinous process device as an alternative for posterior and intercorporal fusion in patients with lumbar spinal stenosis.[@ref68] [@ref69] In Dutch practice, instrumental spondylodesis is not a standard adjuvant in spinal stenosis surgery, and nor is it standard in the modern literature. [@ref35] [@ref36] [@ref40] [@ref42] Nevertheless, two studies compared a wide laminectomy combined with interspinous process device placement against treatment with wide laminectomy combined with posterior and intercorporal fusion.[@ref68] [@ref69] Both studies concluded that adjuvant interspinous process device treatment is as effective as lumbar 360° instrumentation in resolving neurogenic claudication. In addition, a non-randomized study had already shown that patients with intermittent neurogenic claudication treated with bony decompression alone had the same long term satisfactory outcome as did patients treated with bony decompression and adjuvant interspinous process device placement.[@ref70] [@ref71] Furthermore, a recent smaller non-blinded study reported similar results to those presented here. The clinical outcome of patients treated with an interspinous process device was not superior to that in patients treated with bony decompression. As in our study, patients had a higher rate (26% *v* 6%) of reoperation in the interspinous process device group.[@ref72] All studies, including our trial, found no differences between groups with regard to postoperative visual analogue scale leg and back pain.[@ref68] [@ref69]

The results of this study and previous studies lead to the overall conclusion that intermittent neurogenic claudication treated with decompression alone results in a comparable outcome compared with treatment with interspinous process device alone, interspinous process device combined with bony decompression, and 360° instrumented spondylodesis. As instrumented surgery requires more from society and patients, the gold standard for intermittent neurogenic claudication treatment remains the classic bony decompression.

Conclusions
-----------

The hypothesized short term superior effect of treatment with interspinous process device over simple standard surgery was not confirmed by this double blind study. In contrast, treatment with interspinous process devices resulted in a higher reoperation rate and thus prevented a better recovery owing to the lower recovery rate after a second operation. As a spinal research group, we would not recommend the interspinous process device, considering the higher reoperation rate without a short term advantage and most likely with higher costs (interspinous process devices cost at least €2000 (£1704; \$2756)). We doubt if reimbursement of interspinous process devices by society is appropriate. Furthermore, this study shows that future research in spine surgery should be very critical in the evaluation of a so called favorable outcome and weigh this against the disadvantages in robust double blind randomized trials.

### What is already known on this topic

1.  Lumbar spinal stenosis is a common disease and is ranked fifth in terms of the costs of hospital care (owing to the increasing use of instruments)

2.  After surgical intervention, 65% of patients with lumbar spinal stenosis have a favorable outcome

3.  Bony decompression and treatment with interspinous process devices are superior to conservative and non-surgical treatment

### What this study adds

1.  At eight weeks and after one year, the success rate according to the Zurich Claudication Questionnaire for interspinous process device implantation was not superior to that for standard bony decompression

2.  The repeat surgery rate in the interspinous implant group was 29%, compared with 6% for the conventional group
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